Minerva Neurosciences, Inc. (NERV)
$2.53
Insights on Minerva Neurosciences, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 41.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 325.7%
Performance
- $2.49$2.59$2.53
1.58%
Downside
Day's Volatility :3.86%
Upside
2.32%
- $2.26$13.49$2.53
10.67%
Downside
52 Weeks Volatility :83.25%
Upside
81.25%
Returns
| Period | Minerva Neurosciences, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -67.1% | -0.4% | 0.0% |
6 Months | -46.99% | 9.6% | 0.0% |
1 Year | 6.69% | 3.9% | -1.3% |
3 Years | -87.4% | 12.8% | -22.1% |
Highlights
Market Capitalization | 17.3M |
Book Value | - $4.07 |
Earnings Per Share (EPS) | -4.61 |
PEG Ratio | 0.0 |
Wall Street Target Price | 11.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.81% |
Return On Equity TTM | -675.09% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -16.8M |
EBITDA | -23.1M |
Diluted Eps TTM | -4.61 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.57 |
EPS Estimate Next Year | -4.54 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | -1.01 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 334.78%
Technicals Summary
Sell
Neutral
Buy
Minerva Neurosciences, Inc. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Minerva Neurosciences, Inc. | -4.14% | -46.99% | 6.69% | -87.4% | -95.67% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Minerva Neurosciences, Inc. | NA | NA | 0.0 | -3.57 | -6.75 | -0.26 | NA | -4.07 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Minerva Neurosciences, Inc. | Sell | $17.3M | -95.67% | NA | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Federated Hermes Inc
19.32%FMR Inc
7.03%Vanguard Group Inc
2.93%Renaissance Technologies Corp
1.53%BlackRock Inc
1.04%UBS O'Connor LLC
0.92%
Corporate Announcements
Minerva Neurosciences, Inc. Earnings
Minerva Neurosciences, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Organization | Minerva Neurosciences, Inc. |
Employees | 9 |
CEO | Dr. Remy Luthringer Ph.D. |
Industry | Health Technology |
